×
For best experience we recommend to activate Javascript in your browser.
IL13 Receptor alpha 1 antibody (APC)
The APC-conjugated Human Monoclonal anti-IL13 Receptor alpha 1 antibody (Clone ABS1124) (ABIN7804078) specifically detects IL13 Receptor alpha 1.
The antibody is reactive with Human samples.
Catalog No. ABIN7804078
$291.72
Plus shipping costs $50.00
Delivery in 7 to 8 Business Days
Quick Overview for IL13 Receptor alpha 1 antibody (APC) (ABIN7804078)
Target
See all IL13 Receptor alpha 1 (IL13RA1) Antibodies
IL13 Receptor alpha 1 (IL13RA1)
(Interleukin 13 Receptor, alpha 1 (IL13RA1))
Reactivity
All reactivities for IL13 Receptor alpha 1 antibodies
Human
Host
All hosts for IL13 Receptor alpha 1 antibodies
Human
Clonality
All clonalities for IL13 Receptor alpha 1 antibodies
Monoclonal
Conjugate
All conjugates for IL13 Receptor alpha 1 antibodies
This IL13 Receptor alpha 1 antibody is conjugated to APC
Application
Please inquire
Clone
ABS1124
Product Details anti-IL13 Receptor alpha 1 Antibody (APC)
(hide)
Purpose
Anti-Human CD213a1/IL13RA1 Monoclonal Antibody (ABS1124), APC
Characteristics
IgG1, kappa
Isotype
IgG1, kappa
Alternatives
(show)
Application Details
(hide)
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
0.01M PBS, pH 7.4, 0.2 % BSA, 0.05 % Proclin 300.
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freeze-thaw cycles
Storage
4 °C,-20 °C,-80 °C
Storage Comment
4°C for short term (1 week), store at -20°C to -80°C for long term(1 year), Avoid repeated freeze-thaw cycles
Expiry Date
12 months
Target Details for IL13 Receptor alpha 1
(hide)
Target
IL13 Receptor alpha 1 (IL13RA1)
(Interleukin 13 Receptor, alpha 1 (IL13RA1))
Alternative Name
CD213a1
Background
Anti-CD213a1, Anti-IL13RA1, Anti-IL13R
UniProt
P78552
Pathways
JAK-STAT Signaling , Positive Regulation of Immune Effector Process , Production of Molecular Mediator of Immune Response
Recently viewed
(hide)
Chat with us , powered by LiveChat